Insights into the activation and inhibition of angiotensin II type 1 receptor in the mechanically loaded heart

Circulation Journal

Volumn 78, Issue 6, 2014, Pages 1283-1289

  Wu, Jian ^a   You, Jieyun ^a   Wang, Shijun ^a   Zhang, Li ^a   Gong, Hui ^a   Zou, Yunzeng ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Angiotensin II type 1 receptor; Cardiomyocyte hypertrophy; Inverse agonism; Mechanical stress

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; AZILSARTAN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN 1; EPROSARTAN; GUANINE NUCLEOTIDE BINDING PROTEIN; HISTONE DEACETYLASE; IRBESARTAN; ISOPRENALINE; LIM PROTEIN; LOSARTAN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 7; OLMESARTAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE TYK2; SOMATOMEDIN C; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TELMISARTAN; UNINDEXED DRUG; VALSARTAN; ANGIOTENSIN II; RETINA S ANTIGEN;

AORTOCAVAL FISTULA; APOPTOSIS; ARTIFICIAL HEART; AUTOCRINE EFFECT; BINDING SITE; CLINICAL TRIAL (TOPIC); FIBROSING ALVEOLITIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERVOLEMIA; MECHANICAL STRESS; MICROCIRCULATION; NONHUMAN; OXIDATIVE STRESS; PARACRINE SIGNALING; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION; CARDIOMEGALY; HEART CONTRACTION; HEART MUSCLE; METABOLISM; PATHOPHYSIOLOGY;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ARRESTIN; CARDIOMEGALY; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIUM; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 84901290590     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0470     Document Type: Review

References (60)

1. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004; 6: 499-506.
2. Zablocki D, Sadoshima J. Solving the cardiac hypertrophy riddle: The angiotensin II-mechanical stress connection. Circ Res 2013; 113: 1192-1195.
3. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII: The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472.
4. van de Wal RM, van Veldhuisen DJ, van Gilst WH, Voors AA. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: Controversial or common sense? Eur Heart J 2005; 26: 2361-2367.
5. Akazawa H, Komuro I. Mechanical stress induces cardiomyocyte hypertrophy through agonist-independent activation of angiotensin II type 1 receptor. In: Kamkin A, Kiseleva I, editors. Mechanosensitivity of the heart. Dordrecht, the Netherlands: Springer, 2010; 83-95.
6. Yasuda N, Miura S, Akazawa H, Tanaka T, Qin Y, Kiya Y, et al. Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep 2008; 9: 179-186.
7. Miura S, Imaizumi S, Saku K. Recent progress in molecular mechanisms of angiotensin II type 1 and 2 receptors. Curr Pharm Des 2013; 19: 2981-2987.
8. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, et al. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 1995; 92: 3521-3525.
9. Blodow S, Schneider H, Storch U, Wizemann R, Forst AL, Gudermann T, et al. Novel role of mechanosensitive AT1B receptors in myogenic vasoconstriction. Pflugers Arch 2013 October 8, doi: 10. 1007/s00424-013-1372-3.
10. Sadoshima JI, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75: 977-984.
11. Dostal DE, Rothblum KN, Chernin MI, Cooper GR, Baker KM. Intracardiac detection of angiotensinogen and renin: A localized reninangiotensin system in neonatal rat heart. Am J Physiol 1992; 263: C838-C850.
12. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000; 52: 639-672.
13. Storch U, Mederos y Schnitzler M, Gudermann T. G protein-mediated stretch reception. Am J Physiol Heart Circ Physiol 2012; 302: H1241-H1249.
14. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Mizuno T, et al. Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. Circ Res 1995; 77: 258-265.
15. Kent RL, McDermott PJ. Passive load and angiotensin II evoke differential responses of gene expression and protein synthesis in cardiac myocytes. Circ Res 1996; 78: 829-838.
16. Malhotra R, Sadoshima J, Brosius FC, Izumo S. Mechanical stretch and angiotensin II differentially upregulate the renin-angiotensin system in cardiac myocytes in vitro. Circ Res 1999; 85: 137-146.
17. Harada K, Komuro I, Shiojima I, Hayashi D, Kudoh S, Mizuno T, et al. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation 1998; 97: 1952-1959.
18. Miura S, Feng YH, Husain A, Karnik SS. Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 recep-tor. J Biol Chem 1999; 274: 7103-7110.
19. Tilley DG. G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function. Circ Res 2011; 109: 217-230.
20. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006; 7: 589-600.
21. Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB, et al. Enhanced Galphaq signaling: A common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 1998; 95: 10140-10145.
22. Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ, Koch WJ. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 1998; 280: 574-577.
23. Wettschureck N, Rutten H, Zywietz A, Gehring D, Wilkie TM, Chen J, et al. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat Med 2001; 7: 1236-1240.
24. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S. Angiotensin II signal transduction through the AT1 receptor: Novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 2007; 112: 417-428.
25. Ocaranza MP, Jalil JE. Mitogen-activated protein kinases as biomarkers of hypertension or cardiac pressure overload. Hypertension 2010; 55: 23-25.
26. Asrih M, Mach F, Nencioni A, Dallegri F, Quercioli A, Montecucco F. Role of mitogen-activated protein kinase pathways in multifactorial adverse cardiac remodeling associated with metabolic syndrome. Mediators Inflamm 2013; 2013: 367245.
27. Zhou N, Li L, Wu J, Gong H, Niu Y, Sun A, et al. Mechanical stressevoked but angiotensin II-independent activation of angiotensin II type 1 receptor induces cardiac hypertrophy through calcineurin pathway. Biochem Biophys Res Commun 2010; 397: 263-269.
28. Zou Y, Liang Y, Gong H, Zhou N, Ma H, Guan A, et al. Ryanodine receptor type 2 is required for the development of pressure overloadinduced cardiac hypertrophy. Hypertension 2011; 58: 1099-1110.
29. Seta K, Nanamori M, Modrall JG, Neubig RR, Sadoshima J. AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs. J Biol Chem 2002; 277: 9268-9277.
30. Zhai P, Yamamoto M, Galeotti J, Liu J, Masurekar M, Thaisz J, et al. Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 2005; 115: 3045-3056.
31. Wang S, Gong H, Jiang G, Ye Y, Wu J, You J, et al. Src is required for mechanical stretch-Induced cardiomyocyte hypertrophy through angiotensin II type 1 receptor-dependent β-Arrestin2 pathways. PLoS One 2014; 9: e92926, doi: 92910. 91371/journal. pone. 0092926.
32. Rakesh K, Yoo B, Kim IM, Salazar N, Kim KS, Rockman HA. beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci Signal 2010; 3: ra46.
33. Rajagopal K, Whalen EJ, Violin JD, Stiber JA, Rosenberg PB, Premont RT, et al. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci USA 2006; 103: 16284-16289.
34. Godeny MD, Sayeski PP. ANG II-induced cell proliferation is dually mediated by c-Src/Yes/Fyn-regulated ERK1/2 activation in the cytoplasm and PKCζ-controlled ERK1/2 activity within the nucleus. Am J Physiol Cell Physiol 2006; 291: C1297-C1307.
35. Kim J, Ahn S, Rajagopal K, Lefkowitz RJ. Independent beta-arrestin2 and Gq/protein kinase Czeta pathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor. J Biol Chem 2009; 284: 11953-11962.
36. Tilley DG. Functional relevance of biased signaling at the angiotensin II type 1 receptor. Endocr Metab Immune Disord Drug Targets 2011; 11: 99-111.
37. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. Beta-arrestins and cell signaling. Annu Rev Physiol 2007; 69: 483-510.
38. Pretorius L, Owen KL, McMullen JR. Role of phosphoinositide 3-kinases in regulating cardiac function. Front Biosci (Landmark Ed) 2009; 14: 2221-2229.
39. Toischer K, Rokita AG, Unsold B, Zhu W, Kararigas G, Sossalla S, et al. Differential cardiac remodeling in preload versus afterload. Circulation 2010; 122: 993-1003.
40. You J, Wu J, Ge J, Zou Y. Comparison between adenosine and isoflurane for assessing the coronary flow reserve in mouse models of left ventricular pressure and volume overload. Am J Physiol Heart Circ Physiol 2012; 303: H1199-H1207.
41. Kurosawa Y, Katoh M, Doi H, Narita H. Tissue Angiotensin-converting enzyme activity plays an important role in pressure overloadinduced cardiac fibrosis in rats. J Cardiovasc Pharmacol 2002; 39: 600-609.
42. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA 2000; 97: 931-936.
43. Hoffmann S, Krause T, van Geel PP, Willenbrock R, Pagel I, Pinto YM, et al. Overexpression of the human angiotensin II type 1 receptor in the rat heart augments load induced cardiac hypertrophy. J Mol Med (Berl) 2001; 79: 601-608.
44. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003; 362: 767-771.
45. Li L, Zhou N, Gong H, Wu J, Lin L, Komuro I, et al. Comparison of angiotensin II type 1-receptor blockers to regress pressure overloadinduced cardiac hypertrophy in mice. Hypertens Res 2010; 33: 1289-1297.
46. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34.
47. Bauer P, Regitz-Zagrosek V, Kallisch H, Linz W, Schoelkens B, Hildebrandt AG, et al. Myocardial angiotensin receptor type 1 gene expression in a rat model of cardiac volume overload. Basic Res Cardiol 1997; 92: 139-146.
48. Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nabi AH, et al. Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation 2012; 125: 1402-1413.
49. Dent MR, Aroutiounova N, Dhalla NS, Tappia PS. Losartan attenuates phospholipase C isozyme gene expression in hypertrophied hearts due to volume overload. J Cell Mol Med 2006; 10: 470-479.
50. Sentex E, Wang X, Liu X, Lukas A, Dhalla NS. Expression of protein kinase C isoforms in cardiac hypertrophy and heart failure due to volume overload. Can J Physiol Pharmacol 2006; 84: 227-238.
51. Olsen NT, Dimaano VL, Fritz-Hansen T, Sogaard P, Chakir K, Eskesen K, et al. Hypertrophy signaling pathways in experimental chronic aortic regurgitation. J Cardiovasc Transl Res 2013; 6: 852-860.
52. Zhang W, Elimban V, Xu YJ, Zhang M, Nijjar MS, Dhalla NS. Alterations of cardiac ERK1/2 expression and activity due to volume overload were attenuated by the blockade of RAS. J Cardiovasc Pharmacol Ther 2010; 15: 84-92.
53. Nakanishi M, Harada M, Kishimoto I, Kuwahara K, Kawakami R, Nakagawa Y, et al. Genetic disruption of angiotensin II type 1a receptor improves long-term survival of mice with chronic severe aortic regurgitation. Circ J 2007; 71: 1310-1316.
54. Plante E, Lachance D, Beaudoin J, Champetier S, Roussel E, Arsenault M, et al. Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation. Circ Heart Fail 2009; 2: 25-32.
55. Akazawa H, Yabumoto C, Yano M, Kudo-Sakamoto Y, Komuro I. ARB and cardioprotection. Cardiovasc Drugs Ther 2013; 27: 155-160.
56. Yasuda N, Akazawa H, Ito K, Shimizu I, Kudo-Sakamoto Y, Yabumoto C, et al. Agonist-independent constitutive activity of angiotensin II receptor promotes cardiac remodeling in mice. Hypertension 2012; 59: 627-633.
57. Qin Y, Yasuda N, Akazawa H, Ito K, Kudo Y, Liao CH, et al. Multivalent ligand-receptor interactions elicit inverse agonist activity of AT(1) receptor blockers against stretch-induced AT(1) receptor activation. Hypertens Res 2009; 32: 875-883.
58. Miura S, Kiya Y, Kanazawa T, Imaizumi S, Fujino M, Matsuo Y, et al. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol 2008; 22: 139-146.
59. Sukumaran V, Veeraveedu PT, Gurusamy N, Lakshmanan AP, Yamaguchi K, Ma M, et al. Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor. Mol Cell Endocrinol 2012; 351: 208-219.
60. Kim KS, Abraham D, Williams B, Violin JD, Mao L, Rockman HA. Beta-arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury. Am J Physiol Heart Circ Physiol 2012; 303: H1001-H1010.